BrightPath Biotherapeutics
Clinical Trials
2
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC
- Conditions
- Metastatic NSCLC
- First Posted Date
- 2018-01-31
- Last Posted Date
- 2023-08-08
- Lead Sponsor
- BrightPath Biotherapeutics
- Target Recruit Count
- 20
- Registration Number
- NCT03417882
- Locations
- 🇺🇸
St Joseph Hospital of Orange, Orange, California, United States
🇺🇸University of Colorado Cancer Center, Aurora, Colorado, United States
🇺🇸Florida Hosptial Cancer Center- AdventHealth, Orlando, Florida, United States
Phase 1 Study of GRN-1201 in HLA-A*02 Subjects With Resected Melanoma
- Conditions
- Melanoma
- First Posted Date
- 2016-03-02
- Last Posted Date
- 2018-06-14
- Lead Sponsor
- BrightPath Biotherapeutics
- Target Recruit Count
- 18
- Registration Number
- NCT02696356
- Locations
- 🇺🇸
The Christ Hospital Cancer Research, Cincinnati, Ohio, United States
🇺🇸Providence Health and Services, Providence Portland Medical Center, Portland, Oregon, United States
🇺🇸University of Pittsburg, Pittsburgh, Pennsylvania, United States